WHAT IS CLAIMED IS:

1. A compound represented by Formula (I) or (II):



(I)

or



(II)

or a pharmaceutically acceptable salt thereof, wherein

HET-1 is one of the following heterocycles:



HET-2 is one of the following heterocycles:



R^1 is:

(a) H;

(b) C_1-C_6-alkyl, C_2-C_4-alkenyl, C_2-C_4-alkynyl,C_1-C_6-cycloalkyl, or C_1-C_4-alkyl-[C_1-C_6-cycloalkyl], any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^a)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, -$C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) -O- C_1-C_6-alkyl, -O-C_1-C_6-cycloalkyl, -S-C_1-C_6-alkyl or -S-C_1-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1- C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^a)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, -$C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(d) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(e) -OH;

(f) -O-aryl, or –O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –$C(=O)(R^a)$, v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-$N(R^a)(R^b)$, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-$N(R^a)$-, -$N(R^a)$-C(O)-, -$N(R^a)$-C(O)-$N(R^a)$-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C- ;

(g) -OCON(R^a)(R^b), or -$OSO_2N(R^a)$(R^b);
(h) -SH, or -SCON(R^a)(R^b);
(i) NO_2;
(j) NR^aR^b, -$N(COR^a)R^b$, -$N(SO_2R^a)R^b$, -$N(R^a)CON(R^a)_2$, -$N(R^a)CONH_2$, -$N(OR^a)CONR^aR^b$, -$N(R^a)CON(R^a)_2$, or -$N(R^a)SO_2N(R^a)_2$;
(k) -$CH(OR^a)R^a$, -$C(OR^b)CF_3$, -$CH(NHR^b)R^a$, -$C(=O)R^a$, $C(=O)CF_3$, -$SOCH_3$, -SO_2CH_3, -$N(R^a)SO_2R^a$, $COOR^a$, CN, $CONR^aR^b$, -$COCONR^aR^b$, -$SO_2NR^aR^b$, -CH_2O-$SO_2NR^aR^b$, $SO_2N(R^a)OR^a$, -$C(=NH)NH_2$, -CR^a=N-OR^a, CH=$CHCONR^aR^b$, $CONR^a$, $CONHR^a$;
(l) -$CONR^a(CH_2)_{0-2}C(R^a)$(R^b)$(CH_2)_{0-2}CONR^aR^b$;
(m) tetrazolyl, tetrazolinonyl, triazolyl, triazolinonyl, imidazolyl, imidozolonyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrazolonyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, or phenyl, any of which is optionally substituted with 1-3 independent substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) -$C(=O)R^a$, v) C_1-C_6-alkyl , vi) -O-R^a, vii) -NR^aR^b , viii) - C_0-C_4-alkyl -CO-O R^a, ix) -(C_0-C_4-alkyl)-NH-CO-OR^a, x) -(C_0-C_4-alkyl)-CO-NR^a R^b, xi) –$S(O)_{0-2}R^a$, xii) -$SO_2NR^aR^b$, xiii) -$NHSO_2R^a$, xiv) –C_1-C_4-perfluoroalkyl, and xv) –O-C_1-C_4-perfluoroalkyl;
(n) -$C(R^a)$=$C(R^b)$-$COOR^a$, or -$C(R^a)$=$C(R^b)$-$CONR^aR^b$;
(o) piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl or 4-susbstituted piperazin-1-yl, any of which is optionally substituted with 1-3 substituents selected from i) -CN, ii) -



or


;

C(=O)(R^a), iii) C_1-C_6-alkyl , iv) -OR^a, v) -NR^aR^b, vi) -C_0-C_4-alkyl-CO-OR^a, vii) -(C_0-C_4-alkyl)-NH-CO-OR^a, viii) -(C_0-C_4-alkyl)-$CON(R^a)(R^b)$, ix) -SR^a, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$ xiii) -C_1-C_4-perfluoroalkyl and xiv) -O-C_1-C_4-perfluoroalkyl;
R^a is
(a) H;
(b) C_1-C_4-alkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, -$OCONH_2$, -OCONH(C_1-C_4alkyl), -OCON(C_1-C_4alkyl)(C_1-C_4alkyl), -OCONH(C_1-C_4alkyl-aryl), -OCON(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), NH_2, NH(C_1-C_4alkyl), N(C_1-C_4alkyl)(C_1-C_4alkyl), NH(C_1-C_4alkyl-aryl), N(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), $NHCONH_2$, NHCONH(C_1-C_4alkyl), NHCONH(C_1-C_4alkyl-aryl), -NHCON(C_1-C_4alkyl)(C_1-C_4alkyl), NHCON(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), N(C_1-C_4alkyl)CON(C_1-C_4alkyl)(C_1-C_4alkyl), N(C_1-C_4alkyl)CON(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), COO-(C_1-C_4-alkyl),

COOH, CN, $CONH_2$, $CONH(C_1\text{-}C_4alkyl)$, $CON(C_1\text{-}C_4alkyl)(C_1\text{-}C_4alkyl)$, SO_2NH_2, $SO_2NH(C_1\text{-}C_4alkyl)$, $SO_2NH(C_1\text{-}C_4alkyl\text{-}aryl)$, $SO_2N(C_1\text{-}C_4alkyl)(C_1\text{-}C_4alkyl)$, $NHSO_2NH_2$, $-C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) $C_0\text{-}C_4\text{-alkyl-}(C_1\text{-}C_4)\text{-perfluoroalkyl}$; or

(d)$C_1\text{-}C_4\text{-alkyl-aryl}$, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) $-C(=O)(C_1\text{-}C_4alkyl)$, v) $-O(C_1\text{-}C_4\text{-alkyl})$, vi) $-N(C_1\text{-}C_4\text{-alkyl})(C_1\text{-}C_4\text{-alkyl})$, vii) $-C_{1\text{-}10}alkyl$, and viii) $-C_{1\text{-}10}$alkyl,wherein one or more of the alkyl carbons can be replaced by a , - O-, $-S(O)_{1\text{-}2}$-, -O-C(O)- , -C(O)-O-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

R^b is

(a) H; or

(b) $C_1\text{-}C_6$-alkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, $O\text{-}(C_1\text{-}C_4)alkyl$, $S(O)_{0\text{-}2}\text{-}(C_1\text{-}C_4)alkyl$, $-OCONH_2$, $-OCONH(C_1\text{-}C_4alkyl)$, NH_2, NH, $NH(C_1\text{-}C_4alkyl)$, $N(C_1\text{-}C_4alkyl)$, $N(C_1\text{-}C_4alkyl)(C_1\text{-}C_4alkyl)$, $NHCONH_2$, $NHCONH(C_1\text{-}C_4alkyl)$, $NHCON(C_1\text{-}C_4alkyl)(C_1\text{-}C_4alkyl)$, $COO\text{-}(C_1\text{-}C_4\text{-alkyl})$, COOH, CN, pyridyl, piperidinyl, pyrimidinyl, piperazinyl, $CONH_2$ or $(C_1\text{-}C_4alkyl)CONH_2$; or

R^a and R^b, together with the N to which they are attached, can form a 5- or 6-membered ring which optionally contains a heteroatom selected from N, O, and S, and wherein said ring is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) $-C(=O)(R^a)$, v) $-OR^a$, vi) $-NR^aR^b$, vii) $-C_{0\text{-}4}alkyl\text{-}CO\text{-}OR^a$, viii) $-(C_{0\text{-}4}alkyl)\text{-}NH\text{-}CO\text{-}OR^a$, ix) $-(C_{0\text{-}4}alkyl)\text{-}CO\text{-}N(R^a)(R^b)$, x) $-S(O)_{0\text{-}2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) $-NR^aSO_2R^a$, xiii) $-C_{1\text{-}10}$alkyl, and xiv) –O-;

R^2 and R^3 each independently is:

(a) H;

(b) - $C_1\text{-}C_4$-alkyl, or $-O\text{-}C_1\text{-}C_4$-alkyl;

(c) $-C_0\text{-}C_4\text{-alkyl-}C_1\text{-}C_4\text{-perfluoroalkyl}$, or $-O\text{-}C_0\text{-}C_4\text{-alkyl-}C_1\text{-}C_4\text{-perfluoroalkyl}$; or

(d) CN, $N\,R^a\,R^b$, NO_2, F, Cl, Br, I, OH, $OCONR^a\,R^b$, $O(C_1\text{-}C_4\text{-alkyl})CONR^a\,R^b$,$-OSO_2NR^a\,R^b$, $COOR^a$, or $CONR^a\,R^b$;

R^4 and R^5 each independently is:

(a) H;

(b) -C_1-C_6-alkyl, -C_2-C_6-alkenyl, -C_2-C_6-alkynyl or -C_1-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, -O-(C_1-C_4)alkyl, CN, -$N(R^a)(R^b)$, -$N(R^a)$CO-(C_1-C_4)alkyl, $COOR^b$, $CON(R^a)(R^b)$ and phenyl;

(c) -O-C_0-C_6-alkyl, -O-aryl, or -O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –$C(=O)(R^a)$, v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-$N(R^a)(R^b)$, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-$N(R^a)$-, -$N(R^a)$-C(O)-, -$N(R^a)$-C(O)-$N(R^a)$-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

(d) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl; or

(e) CN, NH_2, NO_2, F, Cl, Br, I, OH, $OCON(R^a)(R^b)$ $O(C_1$-C_4-alkyl)$CONR^aR^b$, -$OSO_2N(R^a)(R^b)$, $COOR^b$, $CON(R^a)(R^b)$, or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –$C(=O)(R^a)$, v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-$N(R^a)(R^b)$, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-$N(R^a)$-, -$N(R^a)$-C(O)-, -$N(R^a)$-C(O)-$N(R^a)$-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; and

R^6, R^7 and R^8 each independently is:

(a) H;

(b) C_1-C_6-alkyl, C_2-C_4-alkenyl, C_2-C_4-alkynyl or C_1-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $OCON(R^a)(R^b)$, NR^aR^b, $COOR^a$, CN, $CONR^aR^b$, $N(R^a)CONR^aR^b$, $N(R^a)SO_2NR^aR^b$, $SO_2NR^aR^b$, $S(O)_{0-2}$(C_1-C_4-alkyl), -$C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, and piperazinyl;

(c) -O- C_1-C_6-alkyl, -O-C_1-C_6-cycloalkyl, -S-C_1-C_6-alkyl or -S-C_1-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-

C_4)alkyl, NH_2, $NH(C_1$-C_4-alkyl), $N(C_1$-C_4-alkyl)$_2$, COOH , CN, $CONH_2$, $CONH(C_1$-C_4-alkyl), $CONH(C_1$-C_4-alkyl)$_2$, SO_2NH_2, $SO_2NH(C_1$-C_4-alkyl), tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

(d) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(e) -O-aryl, or -O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –$C(=O)(R^a)$, v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-$N(R^a)(R^b)$, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -$C(O)$-$N(R^a)$-, -$N(R^a)$-C(O)-, -$N(R^a)$-C(O)-$N(R^a)$-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; or

(f) CN, $N(R^a)(R^b)$, NO_2, F, Cl, Br, I, -OR^a, -SR^a, -$OCON(R^a)(R^b)$, -$OSO_2N(R^a)(R^b)$, $COOR^b$, $CON(R^a)(R^b)$, -$N(R^a)CON(R^a)(R^b)$, -$N(R^a)SO_2N(R^a)(R^b)$, -$C(OR^b)R^a$, -$C(OR^a)CF_3$, -$C(NHR^a)CF_3$, -$C(=O)R^a$, $C(=O)CF_3$, -$SOCH_3$, -SO_2CH_3, -$NHSO_2(C_{1-6}$-alkyl), -$NHSO_2$-aryl, $SO_2N(R^a)(R^b)$, -$CH_2OSO_2N(R^a)(R^b)$, $SO_2N(R^b)$-OR^a, -$C(=NH)NH_2$, -CR_a=N-OR_a, CH=CH or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –$C(=O)(R^a)$, v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-$N(R^a)(R^b)$, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -$C(O)$-$N(R^a)$-, -$N(R^a)$-C(O)-, -$N(R^a)$-C(O)-$N(R^a)$-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; or when R^6 and R^7 are present on adjacent carbon atoms, R^6 and R^7, together with the benzene ring to which they are attached, can form a bicyclic aromatic ring selected from naphthyl, indolyl, quinolinyl, isoquinolinyl, quinoxalinyl. benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, and benzimidazolyl, any of which is optionally substituted with 1-4 independent substituents selected from i) halogen, ii) -CN, iii) -NO_2, iv) –CHO, v) -O-C_{1-4}alkyl, vi) -N(C_{0-4}alkyl)(C_{0-4}alkyl), vii) -C_{0-4}alkyl-CO-O(C_{0-4}alkyl), viii) -(C_{0-4}alkyl)-NH-CO-O(C_{0-4}alkyl), ix) -(C_{0-4}alkyl)-CO-N(C_{0-4}alkyl)(C_{0-4}alkyl), x) -S(C_{0-4}alkyl), xi) -S(O)(C_{1-4}alkyl), xii) -SO_2(C_{0-4}alkyl), xiii) -SO_2N(C_{0-4}alkyl)(C_{0-4}alkyl), xiv) -$NHSO_2$(C_{0-4}alkyl)(C_{0-4}alkyl), xv) -C_{1-10}alkyl and xvi) -C_{1-10}alkyl in which one or more of the carbons

can be replaced by a -N(C_{0-6}alkyl)-, -O-, -S$(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(C_{0-6}alkyl)-, -N(C_{0-6}alkyl)-C(O)-, -N(C_{0-6}alkyl)-C(O)-N(C_{0-6}alkyl)-, -C(O)-, -CH(OH), -C=C-, or -C≡C-.

2. The compound according to Claim 1 represented by Formula (I), or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



4. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



5. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



6. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



7. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



8. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



9. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



10. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



11. The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

R6 is other than H and is attached at the ortho position.

12. The compound according to Claim 1 represented by Formula (II), or a pharmaceutically acceptable salt thereof.

13. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



14. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



15. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



16. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



17. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



18. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



19. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



20. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



21. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



and

HET-2 is



22. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



and

HET-2 is



23. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



and

HET-2 is



24. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



25. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



26. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



27. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



28. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



29. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



30. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



31. The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



32. A compound represented by







or a pharmaceutically acceptable salt thereof.

33. A compound represented by



or a pharmaceutically acceptable salt thereof.

34. The compound of Claim 1 represented by



R^6	R^7	R^2	R^1
OCF_3	H	H	H
OCF_3	H	H	
OCF_3	H	H	$-SCH_3$
OCF_3	H	H	$-SO_2CH_3$
OCF_3	H	H	$-SOCH_3$
OCF_3	H	H	NH_2
OCF_3	H	H	$NHSO_2CH_3$
OCF_3	H	H	$N(SO_2CH_3)_2$
OCF_3	H	H	$NHCO(CH_3)_3$
OCF_3	H	H	$CON(CH_3)OCH_3$
OCF_3	H	H	
OCF_3	H	H	CH_3CO
OCF_3	H	H	$CONHC(CH_3)_2COOCH_3$
OCF_3	H	H	$CONHCH_2CH_2CN$
OCF_3	H	H	$CONHC(CH_3)_2COOH$
OCF_3	H	H	$CONHC(CH_3)_2CONH_2$
OCF_3	H	H	$CON(CH_2CH_2)_2NH$
OCF_3	H	H	
OCF_3	H	H	$CONHC(CH_2)_2COOCH_3$

R^6	R^7	R^2	R^1
OCF_3	H	H	$CONHC(CH_2)_2COOH$
OCF_3	H	H	$CONHC(CH_2)_2CONH_2$
OCF_3	H	H	$CON(CH_2)_2N(CH_3)_2$
OCF_3	H	H	$CONHCH_3$
OCF_3	H	H	$CON(CH_3)_2$
OCF_3	H	H	$COOCH_3$
OCF_3	H	H	$CONHCH(CH_3)CONH_2$ (S)
OCF_3	H	H	$CON(CH_2)_2$ 
OCF_3	H	H	$CONHC(CH_3)_3$
OCF_3	H	H	$CON(CH_3)_2CH_2OH$
OCF_3	H	H	$CONHCH(CH_3)CONH_2$ (R)
OCF_3	H	H	
OCF_3	H	CH_3	CH_3
OCF_3	H	CH_3	COOH
OCF_3	H	CH_3	$CONH_2$
OCF_3	H	H	$CONHCH_2CONH_2$
OCF_3	H	Cl	CH_3
OCF_3	H	Cl	$CONH_2$
OCF_3	H	H	$NHCONH_2$
CF_3	H	H	CH_3
CF_3	H	H	H

R^6	R^7	R^2	R^1
CF_3	H	H	COOH
CF_3	H	H	$CONH_2$
CF_3	H	H	
CF_3	H	H	SH
CF_3	H	H	S-$COCH_3$
CF_3	H	H	Cl
CF_3	H	H	CN
CF_3	H	H	
CF_3	5-F	H	CH_3
CF_3	5-F	H	COOH
CF_3	5-F	H	$CONH_2$
CF_3	4-F	H	$CONH_2$
CF_3	4-Cl	H	$CONH_2$
Cl	6-Cl	H	$CONH_2$
CF_3	6-CF_3	H	COOH
CF_3	6-CF_3	H	$CONH_2$
CF_3	4-CF_3	H	CH_3
CF_3	4-CF_3	H	COOH
CF_3	4-CF_3	H	$CONH_2$
CF_3	4-CF_3	H	

R^6	R^7	R^2	R^1
O-Ph	H	H	CH_3
O-Ph	H	H	COOH
O-Ph	H	H	$CONH_2$
H	O-Ph	H	$CONH_2$
Cl	H	H	CH_3
H	3-Cl	H	CH_3
$-SO_2NH$-tBu	H	H	CH_3
$-SO_2NH_2$	H	H	CH_3
-CONH-tBu	H	H	CH_3
$-CONH_2$	H	H	CH_3
-CONH-tBu	H	H	COOH
-CONH-tBu	H	H	$CONH_2$
Cl	3-Cl	H	COOH
Cl	3-Cl	H	$CONH_2$
Cl	3-Cl	H	$COOCH_3$
$-SO_2NH$-tBu	H	H	COOH
$-SO_2NH_2$	H	H	COOH
$-SO_2NH$-tBu	H	H	$CONH_2$
$-SO_2NH_2$	H	H	$CONH_2$
OtBu	H	H	CH_3
OtBu	H	H	COOH

R^6	R^7	R^2	R^1
OtBu	H	H	$CONH_2$
	H	H	CH_3
	H	H	COOH
	H	H	$CONH_2$
OCH_2CF_3	H	H	CH_3
OCH_2CF_3	H	H	COOH
OCH_2CF_3	H	H	$CONH_2$
CHO	H	H	$CONH_2$
H	3-CF_3	H	$CONH_2$
H	4-CF_3	H	$CONH_2$
H	3-F	H	$CONH_2$
H	4-Cl	H	$CONH_2$
H	4-F	H	$CONH_2$
	H	H	$CONH_2$
OCH_3	3-OCH_3	H	$CONH_2$
OCH_3	5-Cl	H	$CONH_2$
CH_3	H	H	$CONH_2$
CH_3	3-F	H	$CONH_2$
	H	H	$CONH_2$
H	4-(CH_2OH)	H	$CONH_2$

R^6	R^7	R^2	R^1
H	3-Cl	H	$CONH_2$
H	3-OEt	H	$CONH_2$
H	4-OEt	H	$CONH_2$
F	H	H	$CONH_2$
CH_3	6-CH_3	H	$CONH_2$
H	4-tBu	H	$CONH_2$
H	4-OCF_3	H	$CONH_2$
H	4-$COCH_3$	H	$CONH_2$
H	3-$COCH_3$	H	$CONH_2$
H	3-(CH_2OH)	H	$CONH_2$
H	4-CN	H	$CONH_2$
H	3-OCF_3	H	$CONH_2$
F	4-F	H	$CONH_2$
H	H	H	$CONH_2$
OCF_3	4-N(Me)SO_2Me	H	CH_3
OCF_3	4-N(Me)SO_2Me	H	$CONH_2$
OCF_3	4-NHCO-tBu	H	CH_3
OCF_3	4-NHCO-tBu	H	COOH
OCF_3	4-NHCO-tBu	H	$CONH_2$
OCF_3	H	H	

R^6	R^7	R^2	R^1
OCF_3	H	H	
OCF_3	H	H	
OCF_3	H	H	
OCF_3	H	H	$-CH_2CONH_2$
OCF_3	H	H	$-CH_2CN$
OCF_3	H	H	$-SO_2NHtBu$
OCF_3	H	H	$-SO_2NH_2$
OCF_3	H	H	$-SO_2NHMe$
OCF_3	H	H	$-CH_2OH$
OCF_3	H	H	-CH(Me)OH
OCF_3	H	H	$-CH_2NHCOCH_3$
OCF_3	H	H	$-CH_2OSO_2NH_2$
OCF_3	H	H	$-NHCH_3$
OCF_3	H	H	$-NH-CH(CH_3)_2$
OCF_3	H	H	

or a pharmaceutically acceptable salt thereof.

35. The compound of Claim 1 represented by



A	R^1
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$

or a pharmaceutically acceptable salt thereof.

36. The compound of Claim 1 represented by



R^6	R^4	R^2	R^1
OCF_3	4-F	H	CH_3
OCF_3	4-F	H	COOH
OCF_3	4-F	H	$COOCH_3$
OCF_3	4-F	H	$CONH_2$
CF_3	4-F	H	$COOCH_3$
CF_3	4-F	H	$CONH_2$
CF_3	4-F	H	CH_3
OCF_3	2-OCH_2Ph	H	CH_3
OCF_3	2-OH	H	CH_3
OCF_3	4-NHAc	H	CH_3
OCF_3	4-NHAc	H	$COOCH_3$
OCF_3	4-NHAc	H	$CONH_2$
OCF_3	2-F	H	CH_3
OCF_3	2-F	H	$COOCH_3$
OCF_3	2-F	H	$CONH_2$
OCF_3	4-Br	H	CH_3
OCF_3	4-Br	H	$COOCH_3$
OCF_3	4-Br	H	$CONH_2$
OCF_3	4-Br	H	COOH
OCF_3	4-Ph	H	CH_3
OCF_3	4-Ph	H	$COOCH_3$
OCF_3	4-Ph	H	$CONH_2$
OCF_3	4-Cl	H	CH_3
OCF_3	4-Cl	H	$COOCH_3$
OCF_3	4-Cl	H	COOH
OCF_3	4-Cl	H	$CONH_2$
OCF_3	2-Cl	H	CH_3
OCF_3	2-Cl	H	$COOCH_3$
OCF_3	2-Cl	H	$CONH_2$
OCH_2CF_3	4-F	H	CH_3
OCH_2CF_3	4-F	H	$COOCH_3$

R^6	R^4	R^2	R^1
OCH_2CF_3	4-F	H	COOH
OCH_2CF_3	4-F	H	$CONH_2$
H	4- OCH_2CF_3	H	$CONH_2$
OCF_3	4-F	CH_3	CH_3
OCF_3	4-F	CH_3	$COOCH_3$
OCF_3	4-F	CH_3	$CONH_2$
F	4- OCH_2CF_3	H	$CONH_2$

or a pharmaceutically acceptable salt thereof.

37. The compound of Claim 1 represented by



R^6	R^2
CF_3	CH_3
CF_3	COOH
CF_3	$CONH_2$
OCF_3	CH_3
OCF_3	COOH
OCF_3	$CONH_2$

or a pharmaceutically acceptable salt thereof.

38. A compound represented by



		
		

or a pharmaceutically acceptable salt thereof.

39. The compound of Claim 1 represented by



R^6	R^1
OCF_3	CH_3
OCF_3	COOH
OCF_3	$COOCH_3$
OCF_3	$CONH_2$

or a pharmaceutically acceptable salt thereof.

40. The compound of Claim 1 represented by



R^6	R^1
OCF_3	CH_3

OCF_3	COOH
OCF_3	$CONH_2$
CF_3	CH_3
CF_3	COOH
CF_3	$CONH_2$

or a pharmaceutically acceptable salt thereof.

41. The compound of Claim 1 represented by



R^6	R^4	R^3	R^2	R^1
OCF_3	H	H	H	CH_3
OCF_3	H	H	H	COOH
OCF_3	H	H	H	$CONH_2$
OCF_3	H	H	H	$COOCH_3$
CF_3	H	H	H	COOH
CF_3	H	H	H	$CONH_2$
Cl	H	H	H	$CONH_2$
OCF_3	H	H	H	$CONHC(CH_3)_2CONH_2$
OCF_3	H	H	H	$COCH_3$
OCF_3	H	H	H	$CH(OH)CH_3$
OCF_3	H	H	H	$COCF_3$

R^6	R^4	R^3	R^2	R^1
OCF_3	H	H	H	$CH(OH)CF_3$
OCF_3	H	H	H	$SOCH_3$
OCF_3	H	H	H	SO_2CH_3
OCF_3	H	H	H	$NHSO_2CH_3$
OCF_3	H	H	CH_3	$NHSO_2CH_3$
OCF_3	H	H	H	$NHCO_2CH_3$
OCF_3	H	H	H	$NHCOCH_3$
OCF_3	H	H	H	$NHCONH_2$
OCF_3	H	H	H	$NHSO_2NH_2$
OCF_3	H	H	H	$N(CH_3)CONH_2$
OCF_3	H	H	CH_3	$N(CH_3)CONH_2$
OCF_3	H	H	$N(CH_3)CONH_2$	CH_3
OCF_3	H	H	H	
OCF_3	H	H	H	
OCF_3	H	H	H	
OCF_3	H	H	H	
OCF_3	H	H	H	
OCF_3	H	H	H	
OCF_3	H	H	H	$-CH_2CH_2CONH_2$

R^6	R^4	R^3	R^2	R^1
OCF_3	H	H	H	$-CH_2CONH_2$
OCF_3	H	H	H	$-CH_2CN$
OCF_3	H	H	H	$-SO_2NH$-tBu
OCF_3	H	H	H	$-SO_2NH_2$
OCF_3	H	H	H	$-SO_2NHMe$
OCF_3	H	H	H	$-CH_2OH$
OCF_3	H	H	H	-CH(Me)OH
OCF_3	H	H	H	$-CH_2NHCOCH_3$
OCF_3	H	H	H	$-CH_2OSO_2NH_2$
OCF_3	H	H	H	$-NHCH_3$
OCF_3	H	H	H	$-NH-CH(CH_3)_2$
OCF_3	H	H	H	NH_2
OCF_3	H	H	CH_3	OCH_3
OCF_3	H	H	OCH_3	CH_3
OCF_3	H	H	CH_3	OH
OCF3	H	H	OH	CH_3
OCF_3	H	NH_2	NH_2	$CONH_2$
OCF_3	F	H	H	$CONH_2$
OCF_3	H	H	CH_3	$OCON(CH_3)_2$
OCF_3	H	H	$OCON(CH_3)_2$	CH_3
OCF_3	H	H	$CONH_2$	OCH_3

R^6	R^4	R^3	R^2	R^1
OCF_3	H	H	CH_3	$O(CH_2)_2N(CH_3)_2$
OCF_3	H	H	$O(CH_2)_2N(CH_3)_2$	CH_3
OCF_3	H	H	OCH_3	$CONH_2$
OCF_3	H	H	CH_3	$NHCH_3$
OCF_3	H	H	Cl	CH_3
OCF_3	H	H	CH_3	H
OCF_3	H	H	H	CH_3
OCF_3	H	H	$CONH_2$	H
OCF_3	F	H	$CONH_2$	H
OCF_3	H	H	H	SCH_3
OCF_3	H	H	H	$S(O)CH_3$
OCF_3	H	H	H	SO_2CH_3
OCF_3	F	H	H	COOH
OCF_3	H	H	H	CHO
OCF_3	H	H	H	$COCH_3$
OCF_3	H	H	H	CN
OCF_3	H	H	H	H
OCF_3	H	H	H	
OCF_3	H	H	H	$CH(OH)CF_3$
OCF_3	H	H	$CH(OH)CF_3$	H
OCF_3	H	H	$CONH_2$	OH

R^6	R^4	R^3	R^2	R^1
OCF_3	H	H	CH_3	CONH-tBu
OCF_3	H	H	H	$COCF_3$
OCF_3	H	H	H	$-OCH_2SO_2NH_2$
OCF_3	H	H	H	$-CH=CHCO_2CH_3$
OCF_3	H	H	H	$-CH(NH_2)CH_2CONH_2$
OCF_3	H	H	$CONH_2$	OCH_3
OCF_3	H	H	H	$-CONHCH(CH_3)CONH_2$
OCF_3	H	H	H	$-CON(CH_3)_2$
OCF_3	H	H	H	$-O(CH_2)_2N(CH_3)_2$
OCF_3	H	H	H	$-CH_2NHCOCH_3$
CF_3	H	H	H	$COOCH_3$
OCF_3	H	H	H	S-$COCH_3$
CF_3	H	H	H	$CONH_2$
OPh	H	H	H	$CONH_2$
OCF_3	H	H	H	$CONHCH_3$
OCF_3	H	H	NH_2	$NHCH_3$
OCF_3	H	H	NH_2	COOPr
Cl	H	H	H	$COOCH_3$
OCF_3	H	H	NH_2	$CONH_2$
Cl	H	H	H	$CONH_2$
OCF_3	H	H	H	$CSNH_2$

R^6	R^4	R^3	R^2	R^1
OCF_3	H	H	CH_3	$CONH_2$
OCF_3	H	H	OCH_3	$CONH_2$
OCF_3	H	H	H	$NHCOCH_3$
OCF_3	H	H	H	$N(COCH_3)_2$
OCF_3	H	H	CH_3	COOH
OCF_3	H	H	$CONH_2$	$CONH_2$
OCF_3	H	H	$CH(CH_3)_2$	$CONH_2$
OCF_3	H	H	$CONH_2$	$CH(CH_3)_2$
OCF_3	H	H	$CH(CH_3)_2$	$CONHC(=NH)NH_2$
OCF_3	H	H	$CH(CH_3)_2$	CONHOH
OCF_3	H	H	H	$NHCONH_2$
OCF_3	H	CH_3	H	$CONH_2$
OCF_3	H	CH_3	$CONH_2$	H
OCF_3	H	H	H	$NHCH_2CONH_2$
OCF_3	H	H	H	$NHC(=NH)NH_2$
OCF_3	H	H	H	$C(=NH)NH_2$
CF_3	H	H	H	COOH
OCF_3	H	Cl	H	$CONH_2$
OCF_3	H	CH_3	COOH	H
OCF_3	H	CH_3	H	COOH
OCF_3	H	NH_2	H	$CONH_2$

R^6	R^4	R^3	R^2	R^1
OCF_3	H	NH_2	H	COOH
OCF_3	H	Cl	H	COOH
OCF_3	H	NH_2	$CONH_2$	H
OCF_3	H	$CONH_2$	H	$CONH_2$
OCH_2CF_3	H	H	CH_3	Cl
OCH_2CF_3	H	H	Cl	CH_3
OCH_2CF_3	H	H	H	CH_3
OCH_2CF_3	H	H	CH_3	H
OCH_2CF_3	H	H	H	$CONH_2$
OCH_2CF_3	H	H	$CONH_2$	H
OCH_2CF_3	H	H	H	H
OCH_2CF_3	H	H	H	COOH
	H	H	H	$COOCH_3$
	H	H	H	$CONH_2$
OCF_3	H	H	H	$CONHC(CH_3)_2CONH_2$
OCF_3	H	H	H	$CH(OH)CH_3$
OCF_3	H	H	H	$NHSO_2NH_2$
OCF_3	H	H	H	$N(CH_3)CONH_2$
OCF_3	H	H	CH_3	$N(CH_3)CONH_2$
OCF_3	H	H	$N(CH_3)CONH_2$	CH_3

or a pharmaceutically acceptable salt thereof.

42. The compound of Claim 1 represented by



R^6	R^7	R^4	R^2	R^1
CF_3	5-F	H	H	$CONH_2$
CF_3	5-F	H	$CONH_2$	H
CF_3	4-CF_3	H	H	$CONH_2$
OCF_3	H	F	H	$CONH_2$
OCF_3	H	F	$CONH_2$	H
CF_3	4-CF_3	H	$CONH_2$	H
CF_3	4-CF_3	H	H	H
Cl	3-Cl	H	H	$COOCH_3$
Cl	4-Cl	H	H	$COOCH_3$
Cl	3-Cl	H	H	$CONH_2$
Cl	4-Cl	H	H	$CONH_2$
Cl	6-Cl	H	H	$CONH_2$

or a pharmaceutically acceptable salt thereof.

43. A compound represented by



or a pharmaceutically acceptable salt thereof.

44. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

45. The pharmaceutical composition according to Claim 42, further comprising a second therapeutic agent selected from the group consisting of: i) opiate agonists, ii) opiate antagonists, iii) calcium channel antagonists, iv) 5HT receptor agonists, v) 5HT receptor antagonists vi) sodium channel antagonists, vii) NMDA receptor agonists, viii) NMDA receptor antagonists, ix) COX-2 selective inhibitors, x) NK1 antagonists, xi) non-steroidal anti-inflammatory drugs, xii) selective serotonin reuptake inhibitors, xiii) selective serotonin and norepinephrine reuptake inhibitors, xiv) tricyclic antidepressant drugs, xv) norepinephrine modulators, xvi) lithium, xvii) valproate, and xviii) neurontin.

46. A method of treatment or prevention of pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

47. A method of treatment of chronic, visceral, inflammatory or neuropathic pain syndromes comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

48. A method of treatment of pain resulting from, or associated with, traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, cancer or chemotherapy, comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

49. A method of treatment of chronic lower back pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

50. A method of treatment of phantom limb pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

51. A method of treatment of HIV- and HIV treatment-induced neuropathy, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain or related neuralgias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

52. A method of administering local anesthesia comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

53. A method of treatment of irritable bowel syndrome or Crohns disease comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

54. A method of treatment of epilepsy or partial and generalized tonic seizures comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

55. A method for neuroprotection under ischaemic conditions caused by stroke or neural trauma comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of thecompound according to Claim 1, or a pharmaceutically acceptable salt thereof.

56. A method of treatment of multiple sclerosis comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically

effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

57. A method of treatment of bipolar disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

58. A method of treatment of tachy-arrhythmias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.